http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2261740-C1

Outgoing Links

Predicate Object
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405
filingDate 2004-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2005-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25cffd1686c0a390134ad4940657b189
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_975b0fbd15a7fbb209f653bc991f3f43
publicationDate 2005-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2261740-C1
titleOfInvention Method for treating patients with glial cerebral tumor
abstract FIELD: medicine, neurooncology. n SUBSTANCE: one should carry out chemotherapy and irradiation till radical dosage. Moreover, 2-3 d before the onset of radiation therapy and during the whole course of irradiation one should indicate the intake of indometacin at daily dosage being 300 mg, and 8-14 d before the end of therapy course or the stage of radiation therapy it is necessary to conduct chemotherapeutic cycle with vincristine at total dosage being 4 mG and lomustine at total dosage 160-240 mg. At performing a split course of irradiation the intake of indometacin should be indicated between the stages. The innovation enables to increase radio sensitivity of malignant tumor, suppress angiogenesis, proliferative activity and increased cytotoxic activity of chemopreparations. n EFFECT: higher efficiency of therapy. n 1 cl, 3 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2498799-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2504342-C2
priorityDate 2004-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493065
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3715
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505305
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5978
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419585571
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3950

Total number of triples: 23.